NCT04395989 2023-12-22
FUTURE-SUPER
Fudan University
Phase 2 Unknown
Clinical Trials
13 trialsNCT06146985 2023-11-28
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Ruijin Hospital
Phase 2 Unknown
NCT04733417 2023-04-13
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05042375 2022-11-17
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05051865 2022-11-17
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04355858 2022-07-26
MULAN
Fudan University
Phase 2 Unknown
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT04679038 2022-01-26
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT04129996 2022-01-11
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
Phase 2 Unknown
NCT05020925 2021-08-25
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT05005468 2021-08-13
CAMFA-L
Shanghai Chest Hospital
Phase 2 Unknown
NCT04866381 2021-04-29
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02336724 2018-04-17
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown